Abstract 10244: Drug Eluting Balloon - PCI is a New Therapeutic Option for Patients with In - Stent Restenosis in Bare Metal Stents
OBJECTIVES: Recent small studies have shown very promising results in treatment of in-stent restenosis in bare metal stents (BMS) with drug eluting balloons (DEB). The purpose of this study was to investigate whether repeat PCI with DEB is an alternative of DES in this group of patients in clinical real life.
METHODS: We retrospectively analyzed our first 84 consecutive patients with BMS in-stent-restenosis, who had been treated with DEB in our department from Apr. 2009 until Nov. 2010 and had been angiographically controlled after a 6 - 9 months period. 91 lesions (LAD: n=44, RCA: n=26, CX: n=14, vein graft: n=7) were treated. In all patients (58 men and 26 women, mean age 67,4 years) we used paclitaxel eluting balloons (Sequent Please®, B. Braun Melsungen, Germany). Mean balloon dimension was 3,09 (SD ± 0,38) mm, mean balloon length 16,17 (SD ± 5,20) mm, mean balloon pressure during PCI was 13,85 (SD ± 3,34) atm and the inflation time 46,51 (SD ± 18,24) sec.
RESULTS: After 6-9 months we found angiographically no significant loss of gain in 85 lesions (93,4%) and repeat in-stent restenosis (>50% of vessel lumen) in 6 lesions (6,6%). In only 3 patients (3,3%) with 70 and 80% in-stent restenoses a second, clinically driven target lesion revascularization (TLR) was performed. 2 patients were treated with DES and 1 patient again with DEB.
CONCLUSIONS: DEB-PCI of the BMS in-stent restenosis is a promising effective therapeutic option with an unexpected low repeat re-stenosis and TLR rate. Thus we consider DEB - PCI as a method of choice of treatment of in-stent-restenosis in clinical practice.
- © 2011 by American Heart Association, Inc.